The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

被引：12

作者：

Hillengass, Jens ^{[1
]}

Cohen, Adam D. ^{[2
]}

Agha, Mounzer E. ^{[3
]}

Delforge, Michel ^{[4
]}

Kerre, Tessa ^{[5
]}

Roeloffzen, Wilfried ^{[6
]}

Einsele, Hermann ^{[7
]}

Goldschmidt, Hartmut ^{[8
]}

Weisel, Katja ^{[9
]}

Raab, Marc S. ^{[10
,11
]}

Scheid, Christof ^{[12
]}

Anguille, Sebastien ^{[13
]}

Sonneveld, Pieter ^{[14
]}

Zweegman, Sonja ^{[15
]}

Schecter, Jordan M. ^{[16
]}

de Braganca, Kevin C. ^{[16
]}

Jackson, Carolyn Chang ^{[16
]}

Vlummens, Philip ^{[17
]}

Varsos, Helen ^{[16
]}

Corsale, Christina ^{[16
]}

Madduri, Deepu ^{[16
]}

Yeh, Tzu-Min ^{[16
]}

Mistry, Pankaj ^{[18
]}

Roccia, Tito ^{[19
]}

Song, Qingxuan ^{[16
]}

Akram, Muhammad ^{[20
]}

Costa Filho, Octavio ^{[20
]}

Geng, Dong ^{[20
]}

Cohen, Yael C. ^{[21
,22
]}

van de Donk, Niels W. C. J. ^{[15
]}

机构：

[1] Roswell Pk, Buffalo, NY USA

[2] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[4] Univ Leuven, Leuven, Belgium

[5] Ghent Univ Hosp, Ghent, Belgium

[6] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[7] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[8] Univ Hosp Heidelberg, GMMG Study Grp, Internal Med 5, Heidelberg, Germany

[9] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[10] Univ Hosp Heidelberg, Heidelberg, Germany

[11] German Canc Res Ctr, Clin Cooperat Unit Mol Hematol Oncol, Heidelberg, Germany

[12] Univ Cologne, Cologne, Germany

[13] Univ Antwerp, Antwerp Univ Hosp, Vaccine & Infect Dis Inst, Ctr Cell Therapy & Regenerat Med, Edegem, Belgium

[14] Univ Med Ctr Rotterdam, Dept Hematol, Erasmus MC, Rotterdam, Netherlands

[15] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[16] Janssen Res & Dev, Raritan, NJ USA

[17] Janssen Res & Dev, Beerse, Belgium

[18] Janssen Res & Dev, High Wycombe, Bucks, England

[19] Janssen Global Serv, Raritan, NJ USA

[20] Legend Biotech USA Inc, Somerset, NJ USA

[21] Tel Aviv Univ, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel

[22] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178882

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[1] CARTITUDE-2 LONG-TERM EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL FOR PATIENTS WITH MULTIPLE MYELOMA AND 1-3 PRIOR LINES OF THERAPY (COHORT A) AND WITH EARLY RELAPSE ( COHORT B)
Glow, Tina
Whittington, Sara
Cohen, Adam
Varsos, Helen
Akram, Muhammad
Hillengass, Jens
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[2] Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (ciltacel) in lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy: CARTITUDE-2 Cohort A
Cohen, Adam
Einsele, Hermann
Delforge, Michel
Hillengass, Jens
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christof
Schecter, Jordan
De Braganca, Kevin
Varsos, Helen
Yeh, Tzu-min
Mistry, Pankaj
Roccia, Tito
Corsale, Christina
Akram, Muhammad
Pacaud, Lida
Nesheiwat, Tonia
Agha, Mounzer
Cohen, Yael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S27 - S28
[3] Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and prior noncellular anti-BCMA therapy: CARTITUDE-2 cohort C
Cohen, Adam
Cohen, Yael
Suvannasankha, Attaya
van de Donk, Niels
San-Miguel, Jesus
De Braganca, Kevin
Jackson, Carolyn
Schecter, Jordan
Vlummens, Philip
Varsos, Helen
Corsale, Christina
Mistry, Pankaj
Song, Qingxuan
Roccia, Tito
Geng, Dong
Zhu, Jieqing
Akram, Muhammad
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S167 - S168
[4] CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in LenalidomideRefractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)
Hillengass, Jens
Cohen, Adam D.
Delforge, Michel
Einsele, Hermann
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christof
Schecter, Jordan M.
De Braganca, Kevin C.
Varsos, Helen
Yeh, Tzu-min
Mistry, Pankaj
Roccia, Tito
Corsale, Christina
Akram, Muhammad
Pacaud, Lida
Nesheiwat, Tonia
Agha, Mounzer
Cohen, Yael C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S411 - S411
[5] Ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma and early relapse after initial therapy: biological correlative analyses and updated clinical results from CARTITUDE-2 Cohort B
Agha, Mounzer
van de Donk, Niels W. C. J.
Cohen, Adam
Cohen, Yael
Anguille, Sebastien
Kerre, Tessa
Roeloffzen, Wilfried
Schecter, Jordan
De Braganca, Kevin
Varsos, Helen
Mistry, Pankaj
Roccia, Tito
Zudaire, Enrique
Corsale, Christina
Akram, Muhammad
Geng, Dong
Nesheiwat, Tonia
Pacaud, Lida
Sonneveld, Pieter
Zweegman, Sonja
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S26 - S26
[6] Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup
Cohen, Adam D.
Voorhees, Peter M.
Martin, Thomas G.
Lesokhin, Alexander M.
Hillengass, Jens
Kaufman, Jonathan L.
Schecter, Jordan Mark
De Braganca, Kevin C.
Varsos, Helen
Corsale, Christina
Mistry, Pankaj
Song, Qingxuan
Koneru, Mythili
Akram, Muhammad
Costa Filho, Octavio
Einsele, Hermann
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1-3 prior lines of therapy: Initial results from CARTITUDE-2
Cohen, Adam
Agha, Mounzer
Madduri, Deepu
Cohen, Yael
Delforge, Michel
Hillengass, Jens
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christoph
Schecter, Jordan M.
De Braganca, Kevin C.
Varsos, Helen
Wang, Liwei
Vogel, Martin
Carrasco-Alfonso, Marlene
Akram, Muhammad
Wu, Xiaoling
Nesheiwat, Tonia
Einsele, Hermann
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S15 - S15
[8] CARTITUDE-2 Cohort B: Efficacy and Safety of Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T-Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients With Multiple Myeloma and Early Relapse After Initial Treatment
Van de Donk, Niels W. C. J.
Delforge, Michel
Agha, Mounzer
Cohen, Adam D.
Cohen, Yael C.
Hillengass, Jens
Anguille, Sebastien
Kerre, Tessa
Roeloffzen, Wilfried
Schecter, Jordan M.
De Braganca, Kevin C.
Varsos, Helen
Wang, Liwei
Vogel, Martin
Zudaire, Enrique
Corsale, Christina
Akram, Muhammad
Geng, Dong
Nesheiwat, Tonia
Pacaud, Lida
Sonneveld, Pieter
Zweegman, Sonja
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 118 - 119
[9] Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort
Ri, Masaki
Suzuki, Kenshi
Ishida, Tadao
Kuroda, Junya
Tsukamoto, Taku
Teshima, Takanori
Goto, Hideki
Jackson, Carolyn C.
Sun, Huabin
Pacaud, Lida
Fujikawa, Ei
Yeh, Tzu-Min
Hatayama, Tomoyoshi
Aida, Kensuke
Sunagawa, Yoshihiro
Iida, Shinsuke
CANCER SCIENCE, 2022, 113 (12) : 4267 - 4276
[10] Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma After 1-3 Prior Lines of Therapy: Updated Results From CARTITUDE-2 Cohort A
Cohen, Yael C.
Cohen, Adam D.
Delforge, Michel
Hillengass, Jens
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christoph
Schecter, Jordan M.
De Braganca, Kevin C.
Varsos, Helen
Yeh, Tzu-Min
Wang, Liwei
Vogel, Martin
Corsale, Christina
Akram, Muhammad
Pacaud, Lida
Nesheiwat, Tonia
Agha, Mounzer
Einsele, Hermann
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 34 - 35

← 1 2 3 4 5 →